Genovis AB (publ.) (GENO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genovis AB (publ.) (GENO) has a cash flow conversion efficiency ratio of 0.059x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr15.90 Million ≈ $1.71 Million USD) by net assets (Skr271.52 Million ≈ $29.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Genovis AB (publ.) - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Genovis AB (publ.)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Genovis AB (publ.) for a breakdown of total debt and financial obligations.
Genovis AB (publ.) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genovis AB (publ.) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fabasoft AG
XETRA:FAA
|
0.034x |
|
Cj Corp Pref
KO:001045
|
0.099x |
|
Friedman Industries Inc. Common Stock
NASDAQ:FRD
|
0.003x |
|
Wam Alternative Assets Ltd
AU:WMA
|
-0.026x |
|
Harbin Bank Co. Ltd
F:5H6
|
-1.253x |
|
Federal Agricultural Mortgage Corporation
NYSE:AGM-A
|
0.060x |
|
First Farms A/S
CO:FFARMS
|
-0.033x |
|
Kelly Partners Group Holdings Ltd
AU:KPG
|
0.259x |
Annual Cash Flow Conversion Efficiency for Genovis AB (publ.) (2008–2025)
The table below shows the annual cash flow conversion efficiency of Genovis AB (publ.) from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Genovis AB (publ.) worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr271.52 Million ≈ $29.22 Million |
Skr32.02 Million ≈ $3.45 Million |
0.118x | -27.56% |
| 2024-12-31 | Skr227.97 Million ≈ $24.53 Million |
Skr37.12 Million ≈ $3.99 Million |
0.163x | -54.15% |
| 2023-12-31 | Skr190.81 Million ≈ $20.53 Million |
Skr67.75 Million ≈ $7.29 Million |
0.355x | +4908.05% |
| 2022-12-31 | Skr125.65 Million ≈ $13.52 Million |
Skr-927.95K ≈ $-99.86K |
-0.007x | -101.83% |
| 2021-12-31 | Skr113.99 Million ≈ $12.27 Million |
Skr45.92 Million ≈ $4.94 Million |
0.403x | +835.02% |
| 2020-12-31 | Skr87.17 Million ≈ $9.38 Million |
Skr3.76 Million ≈ $404.12K |
0.043x | -88.31% |
| 2019-12-31 | Skr35.62 Million ≈ $3.83 Million |
Skr13.13 Million ≈ $1.41 Million |
0.368x | +868.80% |
| 2018-12-31 | Skr26.07 Million ≈ $2.81 Million |
Skr-1.25 Million ≈ $-134.48K |
-0.048x | +89.57% |
| 2017-12-31 | Skr18.19 Million ≈ $1.96 Million |
Skr-8.36 Million ≈ $-899.14K |
-0.459x | +55.57% |
| 2016-12-31 | Skr15.55 Million ≈ $1.67 Million |
Skr-16.08 Million ≈ $-1.73 Million |
-1.034x | +43.40% |
| 2015-12-31 | Skr8.82 Million ≈ $949.39K |
Skr-16.12 Million ≈ $-1.73 Million |
-1.827x | -20.06% |
| 2014-12-31 | Skr14.58 Million ≈ $1.57 Million |
Skr-22.19 Million ≈ $-2.39 Million |
-1.522x | -303.82% |
| 2013-12-31 | Skr33.09 Million ≈ $3.56 Million |
Skr-12.47 Million ≈ $-1.34 Million |
-0.377x | +65.40% |
| 2012-12-31 | Skr13.63 Million ≈ $1.47 Million |
Skr-14.85 Million ≈ $-1.60 Million |
-1.089x | -61.46% |
| 2011-12-31 | Skr18.01 Million ≈ $1.94 Million |
Skr-12.15 Million ≈ $-1.31 Million |
-0.675x | +2.00% |
| 2010-12-31 | Skr15.23 Million ≈ $1.64 Million |
Skr-10.48 Million ≈ $-1.13 Million |
-0.688x | +45.43% |
| 2009-12-31 | Skr10.86 Million ≈ $1.17 Million |
Skr-13.70 Million ≈ $-1.47 Million |
-1.261x | +49.75% |
| 2008-12-31 | Skr6.68 Million ≈ $718.56K |
Skr-16.76 Million ≈ $-1.80 Million |
-2.510x | -- |
About Genovis AB (publ.)
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an… Read more